Breast Cancer Awareness Month
Breast cancer is the most common cancer among women in Sweden. Approximately 20 women are diagnosed every day. Breast cancer treatments have significantly improved over the past twenty years as a result of advances in medical research, technology and understanding of the disease. Today, the five-year survival rate is close to 90 percent, compared to around 75 percent in the 1990s. We've come a long way, but we have further to go.
October marks Breast Cancer Awareness Month and is a good opportunity to reflect and share some insights from our AddLife Group companies.
Our Biomedical and Research and Diagnostics companies build partnerships with world leading global companies who are consistently pushing the boundaries in innovation that help advance cancer treatments. Here are a few examples:
Next generation sequencing: Accessibility to next generation sequencing has transformed genomics and has made a huge impact on access to personalised cancer treatments along with preventative care. @triolab and @Euroclone are active in this expansive area.
Periostin is a prognostic biomarker in breast cancer. @bionordika DK distributes market leading antibodies for detection of Periostin within cancer reseach
Our team at @Biomedica have developed the ELISA assay kit, to measure human serum periostin levels which aids breast cancer diagnosis, prognosis, and treatment decisions.